ICD-9 Codes and Surveillance for Clostridium difficile–associated Disease

We conducted a retrospective cohort study to compare Clostridium difficile–associated disease rates determined by C. difficile–toxin assays and International Classification of Diseases, 9th Revision (ICD-9) codes. The correlation between toxin assay results and ICD-9 codes was good (κ = 0.72, p<0.01). The sensitivity of the ICD-9 codes was 78% and the specificity was 99.7%.


The Study
Data were collected electronically on a retrospective cohort of patients admitted to Barnes-Jewish Hospital in Saint Louis from January 1, 2003, through December 31, 2003. Patients who had only 1 admission of <48 hours and neonates were excluded. Electronic charts were reviewed for patients who had a positive C. difficile-toxin assay or the ICD-9 code indicating C. difficile-associated disease (008.45) (Appendix).
A case of CDAD was defined as a patient with a positive C. difficile-toxin assay (Tech Laboratory C. difficile tox A/B II toxin assay [Tech Laboratory, Blacksburg, VA, USA]) or pseudomembranes seen on colonoscopy.
Because the hospital laboratory performs a C. difficiletoxin assay only on unformed stool samples and stool toxin testing is ordered based on clinical suspicion of CDAD, all patients with a positive toxin assay were considered CDAD case-patients.
Data were analyzed with SPSS 12.0 for Windows (SPSS, Inc., Chicago, IL, USA). Statistical analyses included κ, χ 2 , and Mann-Whitney U tests. A 2-sided p value of 0.05 was considered significant. This study was approved by the Washington University Human Studies Committee.
Thirty-four cases of CDAD were missed by C. difficile-toxin assay results and subsequently identified through chart review (3 missed positive toxins, 26 CDAD patients transferred from other facilities, 3 positive outpatient toxin assays, and 2 diagnosed by colonoscopy), which brought the total number of cases with positive CDAD diagnostics to 696. ICD-9 codes correctly identified 540 of these cases and correctly classified 44,741 admissions as non-CDAD admissions (sensitivity 78%, specificity 99.7%). When the CDAD rate by toxin assays was adjusted for the additional cases, the adjusted CDAD rate was 15.3/1,000 admissions. This rate was not significantly different from the unadjusted CDAD rate by toxin assay results (RR 0.95, 95% CI 0.86-1.06) or the rate by ICD-9 codes alone (RR 1.07, 95% CI 0.97-1.19).

Conclusions
Overall, there was good correlation between C. difficile-toxin assay results and ICD-9 codes. Initially, the CDAD rate by ICD-9 codes appeared higher than the rate by toxin assays. However, once the additional CDAD cases identified through chart review were added, this difference was not significant.
Admissions with only a positive C. difficile-toxin assay and no C. difficile ICD-9 code (CDTA+/ICD9-) were more likely than concordant (CDTA+/ICD9+) admissions to have their first positive toxin assay within 48 hours of discharge. For these admissions, toxin assay results may not yet have been back at the time of discharge or CDAD may not have been considered a primary diagnosis by the physician and therefore not captured by the medical coders.
Antimicrobial drug treatment patterns suggest ICD-9 code only (CDTA-/ICD9+) admissions were patients who were more likely to have a history of CDAD. Metronidazole is first-line therapy for CDAD at our institution. Oral vancomycin is reserved for recurrent or severe cases. The observation that more ICD-9 code only (CDTA-/ICD9+) patients received oral vancomycin indicates that recurrent CDAD may have been suspected in these patients. In these patients, CDAD appears to have been diagnosed on the basis of the patient's history and symptoms instead of by a positive C. difficile-toxin assay. This pattern has been previously reported (12).
True CDAD cases may have been misclassified among the controls. A patient who did not have a positive C. difficile-toxin assay, who was not assigned the CDAD ICD-9 code, and whose diagnosis was made by colonoscopy would have been missed. However, misclassification is unlikely for two reasons. First, after charts were reviewed, only 2 additional patients were identified whose diagnosis  was made by colonoscopy alone. Second, the detection of CDAD cases transferred from other institutions indicates that CDAD cases diagnosed by methods other than the toxin assays are being captured by ICD-9 codes.
Use of ICD-9 codes to study CDAD rates has advantages and disadvantages. ICD-9 codes are readily available from billing databases. In the absence of a national surveillance system for CDAD, ICD-9 codes provide a standard method for determining CDAD rates that can be used at all types of hospitals. However, because ICD-9 codes are assigned at discharge and not on the date of diagnosis, determining which cases are hospital acquired and which are community acquired is difficult. Also, ICD-9 codes are assigned by medical coders, who may not be able to accurately identify a patient's principal diagnoses as well as a physician or medical professional. Despite these limitations, ICD-9 codes can likely be used to identify CDAD cases and track CDAD rates when C. difficile-toxin assay results are not available.
The ICD-9 system of classifying hospital discharge diagnoses is used throughout the United States. The definition for the code 008.45 is consistent between hospitals, although individual coding practices may vary. Although ICD-9 codes have limitations, they are readily available from administrative databases and have been used frequently to identify diagnoses and classify comorbidities (1).
A move to the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10) system is anticipated for US hospitals but the exact time of this transition is not yet known. The ICD-10 system does include a code for CDAD (A04.7, Enterocolitis due to C. difficile), so the ICD-based system presented here could be modified to be used with the updated coding system.